Safety and efficacy of a single intra-articular injection of hyaluronic acid in osteoarthritis of the hip: a case series of 87 patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968565 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2474 (Electronic) Linking ISSN: 14712474 NLM ISO Abbreviation: BMC Musculoskelet Disord Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2000-
    • Subject Terms:
      Osteoarthritis, Hip*/diagnostic imaging ; Osteoarthritis, Hip*/drug therapy ; Osteoarthritis, Knee*/drug therapy; Adult ; Australia ; Female ; Humans ; Hyaluronic Acid/adverse effects ; Injections, Intra-Articular/adverse effects ; Male ; Middle Aged ; Treatment Outcome
    • Abstract:
      Background: Osteoarthritis (OA) is the most prevalent form of joint disease and commonly affects the hip. Hip OA is associated with a high socioeconomic burden. Intra-articular hyaluronic acid (HA) injection may be of benefit but quality evidence for HA use in hip OA is lacking. The purpose of this study was to assess the safety and efficacy of ultrasound guided injection of a high molecular weight, non-animal derived, stabilised HA (NASHA) in patients with mild to moderate hip OA.
      Methods: This single site study is an analysis of prospectively collected outcome data for 87 consecutive patients over a 2-year period who received a single HA (Durolane) injection for symptomatic hip OA. Inclusion criteria were male or female patients over 18-years of age with mild to moderate hip OA on x-ray. Patients with severe hip OA were excluded. The primary outcome measure was a modified Harris Hip Score (mHHS) questionnaire at baseline and 6-weeks with a minimal clinically important difference (MCID) of 10 points. All adverse events were recorded and assessed.
      Results: Data from 87 patients, 49 women and 38 men with mean age of 54 (SD = 10.8) were analysed. At baseline, mean mHHS was 58.47 (SD 14.31). At the 6 week follow up, mean mHHS improved to 71.30 (SD 16.46), a difference of 12.83 (p < 0.01). This was greater than the MCID of 10. No significant adverse events were encountered. Five patients reported short-lived injection site pain.
      Conclusion: A single injection of HA (NASHA) in the setting of hip joint OA was both safe and efficacious in this 87 patient cohort. Improvement in pain and function as measured with mHHS was statistically significant and reached the MCID of 10.
      Trial Registration: The study was retrospectively registered on the 1st of February 2021 in the Australian New Zealand Clinical Trials Registry with registry number ACTRN12621000098831 . All research was performed in accordance with the Declaration of Helsinki.
      (© 2021. The Author(s).)
    • References:
      BMC Musculoskelet Disord. 2017 Jan 6;18(1):3. (PMID: 28056915)
      Am J Sports Med. 2016 Mar;44(3):664-71. (PMID: 26797697)
      BioDrugs. 2012 Apr 1;26(2):101-12. (PMID: 22385405)
      J Arthroplasty. 2016 Apr;31(4):815-9. (PMID: 26639985)
      J Ultrasound Med. 2020 Jan;39(1):113-117. (PMID: 31237389)
      Bone Res. 2016 Mar 01;4:15040. (PMID: 26962464)
      Clin Exp Rheumatol. 2004 May-Jun;22(3):307-12. (PMID: 15144124)
      Orthop J Sports Med. 2019 Jul 19;7(7):2325967119860110. (PMID: 31367647)
      Clin Orthop Relat Res. 2004 Feb;(419):130-7. (PMID: 15021143)
      J Bone Joint Surg Am. 2015 Dec 16;97(24):2047-60. (PMID: 26677239)
      BMC Res Notes. 2015 Oct 05;8:536. (PMID: 26438323)
      Lancet. 2018 Nov 10;392(10159):1859-1922. (PMID: 30415748)
      Pain. 2002 Oct;99(3):501-508. (PMID: 12406526)
      Ann Intern Med. 2012 Aug 7;157(3):180-91. (PMID: 22868835)
      BMC Musculoskelet Disord. 2015 Oct 26;16:321. (PMID: 26503103)
      Open Access Rheumatol. 2018 May 21;10:43-54. (PMID: 29849470)
      Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. (PMID: 31278997)
      Eur Radiol. 2018 Jun;28(6):2345-2355. (PMID: 29318429)
      Eur J Orthop Surg Traumatol. 2018 Jul;28(5):915-922. (PMID: 29164399)
      Clin Med Insights Arthritis Musculoskelet Disord. 2016 Nov 22;9:195-199. (PMID: 27891055)
      Br J Sports Med. 2015 Dec;49(24):1554-7. (PMID: 26405113)
      J Arthroplasty. 2001 Aug;16(5):575-80. (PMID: 11503116)
      Curr Opin Rheumatol. 2018 Mar;30(2):160-167. (PMID: 29227353)
      Sci Rep. 2016 Sep 12;6:32790. (PMID: 27616273)
      Clin Orthop Relat Res. 1997 Nov;(344):179-87. (PMID: 9372770)
      Clin Geriatr Med. 2010 Aug;26(3):355-69. (PMID: 20699159)
      Orthopedics. 2013 Dec;36(12):e1501-8. (PMID: 24579221)
      Arthritis Res Ther. 2011 Mar 20;13(2):R46. (PMID: 21418601)
      Osteoarthritis Cartilage. 2006 Feb;14(2):154-62. (PMID: 16242361)
      Osteoarthritis Cartilage. 2006 Aug;14(8):814-22. (PMID: 16617026)
      J Bone Joint Surg Am. 2007 Jan;89(1):148-57. (PMID: 17200322)
      JAMA. 2012 Jan 18;307(3):294-303. (PMID: 22253396)
      JAMA. 2017 May 16;317(19):1967-1975. (PMID: 28510679)
      Arthritis Res Ther. 2003;5(2):54-67. (PMID: 12718745)
      Ann Rheum Dis. 2014 Jul;73(7):1323-30. (PMID: 24553908)
      Interdiscip Toxicol. 2013 Sep;6(3):111-25. (PMID: 24678248)
      Am J Sports Med. 2016 Aug;44(8):2158-65. (PMID: 26578719)
    • Contributed Indexing:
      Keywords: Durolane; Hip joint; Modified Harris hip score; NASHA
    • Accession Number:
      9004-61-9 (Hyaluronic Acid)
    • Publication Date:
      Date Created: 20210917 Date Completed: 20210920 Latest Revision: 20220531
    • Publication Date:
      20240105
    • Accession Number:
      PMC8447787
    • Accession Number:
      10.1186/s12891-021-04672-0
    • Accession Number:
      34530784